Mast Cell Activation Syndrome Emerging 2025 evidence suggests Tirzepatide, originally developed for metabolic health, may help calm mast cell activation in patients with MCAS. In a recent case series, nearly 9 out of 10 treatment-resistant patients experienced meaningful symptom improvement. Could GLP-1 therapy offer new multi-system support? Read the full blog to learn more.